Skip to main content
. 2022 Mar 17;36(6):855–865. doi: 10.1111/jdv.18010

Figure 3.

Figure 3

Percentage of patients within absolute PASI score categories at weeks 16 and 52 (LOCF). The size of each circle represents the proportion of patients falling into each absolute PASI category; the whole numbers indicate that proportion rounded to the nearest percentage imputed as LOCF. All patients started the trials with a PASI >10 since 1 of the inclusion criteria required patients to have a baseline PASI ≥ 12. LOCF, last observation carried forward; PASI, Psoriasis Area and Severity Index; RZB, risankizumab; UST, ustekinumab.